Our product and pipeline portfolio brings together advanced drug delivery technologies - including proprietary MMX® oral formulations - and AI-enabled medtech platforms. We focus on supporting therapeutic innovation across gastroenterology, dermatology, and endoscopic diagnostics by developing and enabling solutions designed to meet evolving clinical needs and regulatory standards.
Each program is grounded in scientific rigor, from established treatments for chronic conditions to digital systems applied in procedural medicine. Our commitment extends from early-stage research through to clinical application, always with a view to supporting healthcare professionals and the patients they serve.
At every step, we strive to advance care with dedication and responsibility, guided by the needs of clinicians, patients, and the broader healthcare community.
Our solutions
Innovation. Science. Care.
MMX® Technology
MMX® technology is a proprietary multi-matrix system designed to enable targeted and controlled release of active ingredients directly to the colon. By facilitating site-specific delivery, MMX® supports treatment strategies where localized drug exposure is considered clinically appropriate. This approach is intended to optimize therapeutic benefit while limiting systemic absorption, aligning with the goal of safe and effective care.
Our solutions
GI Genius™
Therapeutic Area
Gastroenterology/AI-Assisted Endoscopy
Technology Platform
Deep learning computer-assisted detection system
Regulatory Status
CE Mark (EU), FDA (US), TGA (Australia), Health Canada, MHRA (UK)
Developer/Partnership
Cosmo Pharmaceuticals (MedTech AI Division)
Indication
AI-assisted detection of colorectal lesions during colonoscopy
Patient Information
Device information: FDA 510(k) database and manufacturer labeling
Safety Reporting
Device incidents: FDA MedWatch: fda.gov/medwatch
Eleview®
Therapeutic Area
Gastroenterology/Endoscopy
Technology Platform
Injectable solution with methylene blue for tissue visualization
Regulatory Status
FDA (2015), EMA (2016), Health Canada (2019), PMDA Japan (2020)
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Submucosal injection for endoscopic resection of polyps and mucosal lesions
Patient Information
FDA device labeling available at: accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
Safety Reporting
Device incidents: FDA MedWatch: fda.gov/medwatch
Winlevi® (clascoterone cream 1%)
Therapeutic Area
Dermatology
Regulatory Status
FDA (August 2020), Health Canada (2023), TGA Australia (2024)
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Topical treatment of acne vulgaris in patients aged 12 years and older
Patient Information
FDA labeling: dailymed.nlm.nih.gov | Health Canada product monographs
Pharmacovigilance
Adverse events: pharmacovigilance@cassiopea.com | FDA MedWatch: fda.gov/medwatch
Lialda® / Mezavant® / Mesavancol®
Therapeutic Area
Gastroenterology
Technology Platform
MMX® Multi Matrix System for targeted colonic delivery
Regulatory Status
FDA approved (2007), various international markets
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Treatment of ulcerative colitis in adults and pediatric patients (≥24 kg)
Patient Information
FDA labeling: dailymed.nlm.nih.gov | EMA product information
Uceris® (US) / Cortiment® (EU and international)
Therapeutic Area
Gastroenterology
Technology Platform
MMX® Multi Matrix System for colonic delivery
Regulatory Status
Approved in US, EU, and international markets
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Treatment of active, mild to moderate ulcerative colitis
Patient Information
FDA/EMA labeling via national regulatory websites
Rifamycin SV MMX® (Aemcolo® / Dotecine®/ Stadmycin®)
Therapeutic Area
Gastroenterology/Infectious Disease
Technology Platform
MMX® targeted colonic delivery system
Regulatory Status
FDA approved (Aemcolo®), EMA approved (Dotecine®/ Stadmycin®)
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Treatment of travelers' diarrhea caused by non-invasive E. coli
Patient Information
FDA/EMA approved product labeling and patient leaflets
Pharmacovigilance
Adverse events: +39 02 9333 7980 or cosmotechaemcolo@cosmohc.com
Lumeblue® (China / Global) / Methylene Blue MMX® (EU)
Therapeutic Area
Gastroenterology/Endoscopy
Technology Platform
MMX® oral delivery system for targeted colonic release
Regulatory Status
EMA approved (August 2020), NMPA China approved (June 2024)
Developer/Partnership
Cosmo Pharmaceuticals
Indication
Visual enhancement during colonoscopy for detection of colorectal lesions
Patient Information
EMA product information, NMPA approved labeling
Pharmacovigilance
Adverse events: pharmacovigilance@cassiopea.com
Pipeline
Our development pipeline is guided by a commitment to addressing areas of significant unmet need. We apply proprietary technologies and draw upon robust clinical trial data to advance targeted solutions in gastroenterology, dermatology, and other areas of focus. Each investigational program is developed with a focus on scientific rigor, patient safety, and the requirements of healthcare professionals.
Throughout every stage, we remain dedicated to responsible innovation - supporting better care for patients.
Development pipeline: current focus areas
SkyQuest Technology Consulting. Endoscopy procedures market size, share & trends 2023–2030. Endoscopy Procedures Market Report. 2022. In 2022, the global market for endoscopy procedures was valued at 225.3 million procedures. Available from: https://www.skyquestt.com/report/endoscopy-procedures-market/market-size
Grand View Research. Endoscopy procedures estimates market size report, 2030. Endoscopy Procedures Estimates Market. 2024. The global endoscopy procedures estimates market size was estimated at 191.1 million procedures in 2024 and is projected to reach 207.5 million procedures by 2030. Available from: https://www.grandviewresearch.com/industry-analysis/endoscopy-procedures-estimates-market-report
Ahn SB, Han DS, Bae JH, et al. The miss rate for colorectal adenoma determined by quality‑adjusted, back‑to‑back colonoscopies. Gut Liver. 2012;6(1):64‑70. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3286741/
Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back‑to‑back colonoscopies. Gastroenterology. 1997;112(1):24‑28. Available from: https://pubmed.ncbi.nlm.nih.gov/8978338/
Hong SN, Park JY, Han JP, et al. Adenoma miss rate determined by very shortly repeated colonoscopy after polypectomy. Medicine (Baltimore). 2018;97(38):e12376. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6160154/ or https://journals.lww.com/md-journal/fulltext/2018/09210/adenoma_miss_rate_determined_by_very_shortly.23.aspx
Bisschops R, East JE, Hassan C, et al. Lower adenoma miss rate of computer‑aided detection‑assisted colonoscopy versus routine colonoscopy in a randomized trial. Gastroenterology. 2020;159(3):1252‑1261.e3. Available from: https://pubmed.ncbi.nlm.nih.gov/32562721/
Park SK, Kim HS, Yang HJ, et al. Miss rate of colorectal neoplastic polyps and risk factors for missed polyps in consecutive colonoscopies. Intest Res. 2017;15(3):411‑418. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5478767/
Hong SN, Park JY, Han JP, et al. Adenoma miss rate determined by very shortly repeated colonoscopy after polypectomy. Medicine (Baltimore). 2018;97(38):e12376. Available from: https://journals.lww.com/md-journal/fulltext/2018/09210/adenoma_miss_rate_determined_by_very_shortly.23.aspx